Mechanisms of Insulin Resistance Formation in Polycystic Ovarian Disease and Therapeutic Effects from Myo Inositol

Chernukha, Chernukha G.E.; Udovichenko, M.A.; Naydukova, A.A.

doi:10.31550/1727-2378-2019-166-11-55-60

Cited by 4 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Инозитол содержится во многих продуктах питания в форме фитиновой кислоты или ее солей (фитатов). Однако фитиновая кислота плохо усваивается в желудочнокишечном тракте [47]. Существует 9 изомеров инозитола.…”

Section: мио-инозитолunclassified

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Dolgikh,

Bulgakova,

Sharonova

et al. 2024

ECG

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a common endocrine disease in women of reproductive age. The prevalence of this pathology is approximately 15-20%. PCOS is characterized by hyperandrogenism, hirsutism, menstrual irregularities, and polycystic ovaries. More than half of patients with PCOS have a metabolic syndrome, the main component of which is visceral obesity and insulin resistance, which play an important role in the pathophysiology of PCOS. Insulin resistance is a marker of cardiometabolic risk and can lead to cardiovascular disease and carbohydrate metabolism disorders up to type 2 diabetes mellitus (DM2). Therefore, in the treatment of patients with PCOS, an important aspect is the impact on insulin sensitivity and body weight. This review focuses on various groups of drugs that can potentially have a positive effect on metabolic disorders in PCOS. Among them are metformin, drugs with an incretin effect, as well as drugs for weight loss. Given the similarity of the metabolic and pathological features of PCOS and DM2, as well as the diversity of therapeutic options, there is a potential for expanding the strategy for the treatment of metabolic disorders in PCOS, including through antidiabetic drugs, which, however, requires further study. It should be noted that surgical treatment of obesity also has a beneficial effect and contributes to the normalization of the menstrual cycle and the normalization of the hormonal and metabolic profile in patients with PCOS and severe obesity.

show abstract

Section: мио-инозитолunclassified

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Dolgikh,

Bulgakova,

Sharonova

et al. 2024

ECG

View full text Add to dashboard Cite

show abstract

Polycystic ovaries: problematics, etiology, pathogenesis (literary review)

Bakurinskikh

Yakushev

Ten

et al. 2022

Perm Medical Journal

View full text Add to dashboard Cite

The polycystic ovary syndrome (POS) is a common hormonal disorder in women all over the world; it is characterized not only by reproductive disturbances but by endocrine and metabolic as well. Women with POS are subjected to an increased risk for the development of type 2 diabetes mellitus, metabolic syndrome and sterility. This article presents information on POS problems, its history. The main etiological factors predisposing to the development of polycystic ovaries syndrome are highlighted. Besides, actual data on pathogenetic theories of POS development are presented.

show abstract

Polycystic ovary syndrome: approach to correction of metabolic disorders

Калугина

Татарчук

2020

View full text Add to dashboard Cite

Objective: to study the reliability of working hypothesis about positive effect of plant adaptogens with hepatoprotective and anti-inflammatory activity in correction of metabolic complications of polycystic ovary syndrome (PCOS) and to study the possibility of including schisandrin into treatment, choice of which is due to its properties to improve tissue sensitivity to insulin, hepatoprotective, hypolipidemic, anti-inflammatory and antioxidant effects.Materials and methods. A comparative prospective study of 60 patients aged 18–38 years with PCOS (phenotype A) was carried out. Criteria for inclusion in the study were: a confirmed diagnosis with increased ovaries and oligo-/anovulation, increased level of ovarian androgens; body mass index (BMI) from 25 to 30.1 kg/m2. All women underwent a general clinical examination evaluating anthropometric parameters and BMI, the presence of clinical manifestations of hyperandrogenism (hirsutism and androgenic dermatopathy) on a Ferriman-Gallwey scale, ultrasound of the genital organs, assessment of progesterone and insulin resistance based on the NOMA index on the 22–24th day of the menstrual cycle. Рatients were divided into 2 equal groups depending on the therapy: women in the main group were prescribed schisandrin 1 tablet (250 mg) three times a day for 12 weeks, patients in the control group received recommendations on diet and physical load.Results. The resulting course of treatment with schisandrin showed restoration of regular menstrual cycles in 40% of patients (versus 16.6% at the beginning of the study) due to a 1.4-fold increase in progesterone level, improvement of skin condition, BMI normalization. A positive effect of treatment on the metabolic status was also noted: a significant decrease in HOMA indices was observed, and transaminases levels were normalized.Conclusions. For a comprehensive examination of patients with PCOS, especially those who are overweight and obese, it is necessary to include a HOMA index assessment, functional liver tests, ultrasound of the hepatobiliary system with elastography. Complex therapy regimen should include schisandrin for prevention of metabolic disorders in women with PCOS and overweight.

show abstract

Mechanisms of Insulin Resistance Formation in Polycystic Ovarian Disease and Therapeutic Effects from Myo Inositol

Cited by 4 publications

References 49 publications

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Polycystic ovaries: problematics, etiology, pathogenesis (literary review)

Polycystic ovary syndrome: approach to correction of metabolic disorders

Contact Info

Product

Resources

About